MedTrace Logo

Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery

NCT03600168 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-09-09

No results posted yet for this study

Summary

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

Conditions

  • Liver Resection

Interventions

DEVICE

PuraStat®

Synthetic haemostatic material

Sponsors & Collaborators

  • 3-D Matrix Europe SAS

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-02
Primary Completion
2019-09-04
Completion
2020-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600168 on ClinicalTrials.gov